Liothyronine (T3) 80 mcg SR cap
Published February 5, 2020 · Recall initiated: December 18, 2019
Summary
FDA records drug Class II recall D-0807-2020, published February 5, 2020 and initiated December 18, 2019. Recalling firm: MPRX, Inc. dba Medical Park Pharmacy; Status: Terminated; Reported quantity: 5 bottles; Lot: Lot: 61253:42 Use by: 04/01/2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- MPRX, Inc. dba Medical Park Pharmacy
- Distributor
- TX
- Lot
- Lot: 61253:42 Use by: 04/01/2020
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDASquaric Acid 0.1% Topical Solution (Clinic) 30 mLFebruary 5, 2020
- FDAProgesterone 200 mg TrocheFebruary 5, 2020
- FDANaltrexone 4.5 mg capsuleFebruary 5, 2020
- FDATadalafil 6 mg CapsuleFebruary 5, 2020
- FDALidocaine/Priloc/PE 30/5/0.25% 30 GM jarsFebruary 5, 2020
- FDALiothyronine (T3) 92.5 MCGFebruary 5, 2020
Questions about this recall
Was Liothyronine (T3) 80 mcg SR cap recalled?
Yes. FDA published recall D-0807-2020 on February 5, 2020. Reported hazard: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.
What should I do if I have this product?
Voluntary: Firm initiated · Letter